- In March 2024, Abbott Laboratories introduced a next-generation clinical chemistry analyzer as part of its Alinity suite, designed to deliver high-throughput testing with reduced sample volumes and faster turnaround times. The system incorporates intelligent processing algorithms and modular scalability to meet the evolving needs of high-volume labs in the U.S. This development underscores Abbott’s ongoing commitment to improving laboratory efficiency and diagnostic accuracy through innovation in automated chemistry testing platforms
- In February 2024, Roche Diagnostics launched enhancements to its cobas® pro integrated solutions platform in the U.S., aimed at improving analytical performance and streamlining lab operations. The upgrade features advanced automation and connectivity options, allowing seamless integration with Laboratory Information Systems (LIS) and supporting remote diagnostics. This move demonstrates Roche’s focus on delivering comprehensive, future-ready solutions for U.S. healthcare providers seeking to modernize their diagnostic infrastructure
- In January 2024, Beckman Coulter Diagnostics (a Danaher company) announced the FDA clearance of new assays for its AU clinical chemistry analyzers, expanding the test menu to include enhanced cardiac and liver biomarkers. These additions reflect the company’s strategy to strengthen its presence in U.S. labs by offering comprehensive diagnostic capabilities for chronic and acute conditions. The development supports improved patient care through faster, more detailed biochemical analysis
- In December 2023, Siemens Healthineers introduced its Atellica® CH Analyzer to select U.S. healthcare systems, integrating AI-enabled features and real-time quality control systems. Designed for both standalone and networked environments, the analyzer aims to reduce manual workloads while maintaining high accuracy. This launch highlights Siemens’ investment in automation and clinical decision support within the U.S. diagnostics space
- In November 2023, Ortho Clinical Diagnostics announced a strategic partnership with a major U.S. hospital chain to deploy its Vitros® XT 7600 analyzers across multiple locations. The partnership includes training, service integration, and remote analytics capabilities, showcasing the company's focus on scalability and value-added service in the competitive U.S. clinical diagnostics market
